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Abstract
Background: UK National Dementia Strategies prioritise fair access to dementia treatments for the whole population. We
investigated for the ﬁrst time inequalities in NHS national dementia prescribing and how they have varied between UK coun-
tries and over time.
Method: we investigated the association between Townsend deprivation score and anti-dementia drug prescribing in 77,045
dementia patients from UK primary care records from 2002 to 2013.
Results: we included 77,045 patients with recorded dementia diagnosis or anti-dementia drug prescription. Least deprived
patients were 25% more likely to be initiated on anti-dementia drugs than the most deprived (adjusted incidence rate ratio 1.25,
95% conﬁdence interval 1.19–1.31). This was driven by data from English practices where prescribing rates were consistently
lower in more deprived patients compared with Scotland, Northern Ireland and Wales, where prescribing was not related to de-
privation quintile. Compared with English practices, anti-dementia medication was prescribed more often in Northern Irish
(1.81, 1.41–2.34) and less in Welsh practices (0.68, 0.55–0.82), with a trend towards more prescribing in Scottish practices
(1.14, 0.98–1.32). Drug initiation rates were also higher in younger people and men.
Conclusion: four years after the English National Dementia Strategy, there is no evidence that the Strategy’s key objective of
reducing treatment inequalities is being achieved. Higher overall anti-dementia drug prescribing in Scottish and Northern Irish
practices, and differing clinical guidelines in Scotland from other UK countries might explain greater equality in prescribing in
these countries. Strategies to offer treatment to more deprived people with dementia in England are needed.
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Introduction
Around 6.5% of the UK population aged 65 and over have
dementia [1, 2]. Cholinesterase inhibitors and memantine
beneﬁcially affect cognitive, functional and global outcomes
in Alzheimer’s disease and are the only drugs NICE
(National Institute for Health and Clinical Excellence) rec-
ommend for dementia.
NICE recommended cholinesterase inhibitors for mild and
moderate Alzheimer’s disease in 2001; restricted this to moderate
dementia in 2006 on cost beneﬁt grounds, then reversed these
restrictions in 2009; since 2011, they have also recommended
memantine. NICE technology appraisals apply in England,
Wales and Northern Ireland. NHS Scotland [3] allows Scottish
clinicians to follow NICE or Scottish Intercollegiate Guidelines
Network (SIGN) guidelines; the less restrictive SIGN guidelines,
recommending cholinesterase inhibitors for any severity de-
mentia since 2006 are probably more inﬂuential [4]. National
Dementia Strategies for England (2009), Scotland (2010) and
Wales (2009) promote fair access to treatment. UK anti-dementia
drug prescriptions [5] and specialist referrals for dementia have
increased in the last decade, alongside memory services invest-
ment driven by the Dementia strategies [6] and inclusion of
Dementia in the UK Quality and Outcomes Framework (QOF)
pay-for-performance system; the proportion of dementia undiag-
nosed, while still substantial, has decreased in recent years [7].
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Inequalities in healthcare access reduce the effectiveness
of health policies. People from minority ethnic groups are
diagnosed with dementia later in the illness, and those from
Black ethnic groups are 30% less likely to receiving cholin-
esterase inhibitors [8]. Socioeconomic inequalities are less
well studied. In Australia (2003–10), cholinesterase inhibitors
were prescribed more to less deprived people [9]. In small,
probably unrepresentative UK studies, people with dementia
who were younger, more deprived [10], from a lower social
class or less educated were least likely to receive anti-
dementia drugs [11].
In the current study, we investigated for the ﬁrst time in-
equalities in NHS national dementia prescribing and how
they have varied over the past decade, which has seen an
abundance of dementia policymaking. Our objectives were
to test our hypothesis that people in the most deprived quin-
tile were less likely than the least deprived to be prescribed
anti-dementia drugs between 2002 and 2013. We also
hypothesised a priori that: (i) National Dementia Strategies
and reversal of previous restrictions in prescribing for mild
dementia reduced deprivation inequalities in initiation of pre-
scribing after 2010, by reducing a tendency towards less pre-
scribing in more deprived areas, where primary care is
relatively under-resourced [12] and patients may be less
knowledgeable and assertive in seeking out treatment [13];
(ii) less restrictive recommendations in Scotland compared
with other UK countries between 2006 and 2009 resulted in
less inequality by deprivation in Scotland.
Methods
Data source
Approximately 98% of the UK population are registered
with a GP [14] and over 90% of NHS contacts are in general
practice [15]. The Health Improvement Network (THIN) is
a primary care database of 12 million patients (http://www.
csdmruk.imshealth.com). Anonymised patients’ data are col-
lected from over 500 participating practices that are broadly
representative of UK practices in terms of patients’ age and
sex, practice size and geographical distribution [16]. Broadly
reﬂecting the distribution of UK practices [13], most THIN
practices are in England (73%), with 15% in Scotland, 8%
in Wales and 4% in Northern Ireland. GPs record medical
diagnoses and symptoms using the Read classiﬁcation
system [17]. Prescription information is entered automatical-
ly. Information recorded for each registered person includes
year of birth, sex, diagnoses and symptom records, prescrip-
tions and quintiles of deprivation score.
Study population
We included patients aged 50 or over with a dementia Read
code or at least one anti-dementia drug prescription. We
included patients with an anti-dementia drug prescription
even if no dementia diagnosis was recorded, as they are only
prescribed for dementia. for each practice, we only used data
from the date when death recording was considered com-
plete, and computer usage levels acceptable [18, 19]. The
cohort was restricted to patients for whom deprivation score
quintile was available (98%). This was a dynamic cohort,
with patients entering and leaving at difference times.
Patients were included from the latest of registration date, age
50 years, or 1st January 2002. Patients were followed from
their earliest record of dementia or anti-dementia drug pre-
scription, and follow-up was censored at the earliest date of
death, leaving the practice, or 31st December 2013.
Measurements
We included people with Read codes for non-speciﬁc demen-
tia, Alzheimer’s disease, vascular dementia and all other
dementias. The GPs do not always record the subtype diag-
nosed by a specialist. We examined deprivation by using quin-
tiles of the Townsend score [20], which is linked to a patient’s
UK postcode and is based on levels of unemployment, car
ownership, home ownership and household overcrowding
recorded in the 2001 census. In a sensitivity analysis, we used
an alternative measure of deprivation: quintiles of the 2007
Index of Multiple Deprivation (IMD) [21] for England. The
IMD is based on levels of income, employment, health, educa-
tion, crime, access to services and living environment. It is
only internally valid within countries, and so this sensitivity
analysis was restricted to English practices. We deﬁned initi-
ation of anti-dementia therapy as receiving at least one pre-
scription and continuation as receiving 60 consecutive days of
doses [22].
Analysis
Using Stata version 13.1, we calculated incidence rate ratios of
anti-dementia drug initiation in a univariable analysis stratiﬁed
by age, gender, country, deprivation score and time period. We
used a Poisson multivariable regression to measure associations
between deprivation and anti-dementia drug prescribing after
accounting for covariates. Analyses used random-effects
regression to account for practice clustering effects. As we
found a signiﬁcant interaction between deprivation quintile and
country, we ﬁtted separate models to data from each country
to investigate the effect of deprivation on anti-dementia drug
prescribing. We repeated analyses to investigate drug continu-
ation. We conducted a sensitivity analysis including only those
with a known subtype diagnosis for which medication is
recommended (Alzheimer’s disease, mixed Alzheimer’s and
vascular and Lewy Body and Parkinson’s disease dementias).
We repeated our main analysis in English practices using the
2007 IMD for England instead of Townsend score to measure
deprivation. This work was supported by The Dunhill Medical
trust (R296/0513).
Results
We included 77,045 patients with a record of dementia or an
anti-dementia drug prescription, with a median (inter-quartile
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range [IQR]) follow-up of 1.8 (0.8–3.3) years. Table 1 shows
study cohort characteristics. Dementia diagnosis subtype was
unspeciﬁed for 36,108 (47%) patients; 23,351 (30%) patients
had an Alzheimer’s or mixed dementia diagnosis; and 15,346
(20%) patients had a vascular dementia diagnosis.
Drug initiation
A total of 28,337 (37%) patients received at least one anti-
dementia drug prescription, with an overall drug initiation
rate of 23 per 100 person-years. In total, 17,704 (62%) of
prescriptions were for donepezil, 3,541 (12%) rivastigmine,
4,232 (15%) galantamine and 2,860 (10%) memantine. The
crude drug initiation rate in the most deprived dementia
patients was 21.7 per 100 person-years, but 26.1 per 100
person-years in the least deprived (Table 2). Least deprived
patients were 25% more likely to be initiated on an anti-
dementia drug than the most deprived patients (adjusted in-
cidence rate ratio [IRR] 1.25, 95% conﬁdence interval [CI]
1.19–1.31). Drug initiation rates were higher in younger
people and men. Initiation rates were lowest in Wales (IRR
0.68, 95% CI 0.55–0.82) and highest in Northern Ireland
(1.81, 1.41–2.34) and Scotland (1.14, 0.98–1.32) (Table 2).
Drug initiation rates appeared to be slightly lower during
2006–09 compared with 2002–05 and 2010–13 in all coun-
tries (Figure 1). In English practices, a similar relationship
was observed to that seen in the whole UK, with rates of
prescribing increasing with decreasing deprivation (least
deprived compared with the most deprived group: IRR 1.27,
95% CI 1.20–1.34). In the other UK countries, there was no
such relationship between deprivation quintile and prescrib-
ing (Table 3). Figure 1 indicates that in Wales, greater depriv-
ation may have been associated with less prescribing before
2010, although from 2010–13, this relationship is no longer
evident.
Drug continuation
There was no signiﬁcant difference in the likelihood of
people from different deprivation quintiles receiving anti-
dementia drugs for at least 60 days. Continuation rates were
similar between countries.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Cohort characteristics at baseline
Characteristics n (%)
Sex
Male 27,773 (36)
Female 49,272 (64)
Age at baseline
Median (IQR) 82 (77–87)
Country
England 59,498 (77)
Scotland 10,231 (13)
Wales 4,712 (6)
Northern Ireland 2,604 (3)
Year of first dementia record
2002–05 19,074 (25)
2006–09 26,461 (34)
2010–13 31,510 (41)
Townsend quintile
1 (least deprivation) 18,547 (24)
2 18,114 (24)
3 16,846 (22)
4 14,570 (19)
5 (greatest deprivation) 8,968 (12)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Rates and predictors of anti-dementia drug initiation
Characteristics Rate of drug initiation
per 100 person-years
IRRa (95% CI)
Unadjusted Adjusted
Sex
Male 25.0 1 1
Female 22.1 0.87 (0.85–0.89) 0.96 (0.94–0.98)
Age
per 10 year increase 0.77 (0.76–0.78) 0.76 (0.75–0.77)
Country
England 22.5 1 1
Scotland 25.8 1.17 (1.02–1.36) 1.14 (0.98–1.32)
Wales 14.2 0.72 (0.59–0.87) 0.68 (0.55–0.82)
Northern Ireland 44.7 1.90 (1.48–2.44) 1.81 (1.41–2.34)
Year
2002–05 22.5 0.74 (0.72–0.77) 0.72 (0.69–0.74)
2006–09 19.5 0.68 (0.66–0.69) 0.67 (0.65–0.68)
2010–13 25.9 1 1
Townsend quintile
1 (least deprivation) 26.1 1.24 (1.18–1.30) 1.25 (1.19–1.31)
2 22.9 1.11 (1.06–1.17) 1.14 (1.09–1.20)
3 22.6 1.12 (1.07–1.18) 1.13 (1.08–1.19)
4 20.9 1.06 (1.01–1.12) 1.07 (1.02–1.12)
5 (greatest deprivation) 21.7 1 1
aResults from multivariable Poisson regression models, including practice as a random effect. Adjusted IRRs are adjusted for the other covariates shown.
IRR, incidence rate ratio.
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Sensitivity analyses
When we restricted the analysis to people with a known diag-
nosis for which anti-dementia drugs are indicated (primarily
Alzheimer’s and mixed dementias): the least deprived had a
7% higher rate of drug initiation than the most deprived
group (IRR 1.07, 95% CI 1.01–1.15). Using IMD instead of
Townsend score to measure deprivation in England, we
observed a similar relationship between deprivation and anti-
dementia drug prescribing; the least deprived had a 33%
higher rate of drug initiation than the most deprived group
(IRR 1.33, 95% CI 1.24–1.41).
Discussion
People with dementia who were least deprived were 25%
more likely than the most deprived to be prescribed anti-
dementia medication; this was driven by data from English
practices, where the least deprived were 27% more likely to
be prescribed these drugs. Dementia drug treatments have
probably been more available to people who are less
deprived, because they better negotiate healthcare systems,
and more frequently ask for them [13]; and less available to
those from more deprived areas, who have on average more
morbidity, attend relatively under-resourced practices and are
Figure 1. Plots of initiation rates over time by Townsend score and country.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3. Association between Townsend quintile and anti-dementia drug initiation in the four constituent countries of the UK
Characteristics England Scotland Wales Northern Ireland
IRR (95% CI) IRR (95% CI) IRR (95% CI) IRR (95% CI)
Townsend quintile
1 (least deprivation) 1.27 (1.20–1.34) 1.15 (1.01–1.30) 1.09 (0.86–1.38) 1.00 (0.84–1.18)
2 1.11 (1.05–1.17) 1.34 (1.21–1.49) 0.94 (0.74–1.19) 1.07 (0.90–1.28)
3 1.09 (1.03–1.16) 1.32 (1.19–1.47) 0.95 (0.76–1.19) 1.16 (0.98–1.37)
4 1.02 (0.96–1.08) 1.30 (1.17–1.44) 0.91 (0.72–1.16) 1.08 (0.89–1.30)
5 (greatest deprivation) 1 1 1 1
Results from multivariable Poisson regression models, including practice as a random effect. IRRs adjusted for sex, age and calendar time.
IRR, incidence rate ratio.
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less able to attend appointments, especially in rural areas [12,
23]. These differences are signiﬁcant, although of a lesser
magnitude to those reported in other Western countries [6].
In England, signiﬁcant inequality remained throughout the
decade studied despite the 2010 National Dementia strategy
and more inclusive 2009 NICE guidelines [24]. Guidelines
can take years to be fully implemented [25], so these policies
could be driving inequality reductions not fully realised,
although our study extended 4 years after guideline publica-
tion. In Wales, there appeared to be less inequality after 2010;
this could be a chance ﬁnding or indicate that these policies
have more effectively reduced inequality in Wales.
People in Northern Ireland with dementia are more likely
than those in England to be prescribed anti-dementia drugs,
and there was a trend towards more prescribing in Scotland.
We hypothesised that the less restrictive Scottish recommen-
dations between 2006 and 2009 might have decreased dispar-
ity in their use compared with England, because people
with fewer resources are less able to circumvent restrictions
[13]. The disparities in treatment availability that we found in
English practices were not demonstrated in Scottish or
Northern Irish practices. Perhaps the higher overall prescrib-
ing rates in Scotland and Northern Ireland helped prevent
prescribing inequalities. In Scotland and Northern Ireland, a
greater proportion of patients with dementia have a recorded
diagnosis, compared with English and Welsh practices, so
people with dementia could also be more likely to receive a
timely diagnosis in these countries [26].
The proportion of prescribing taking place in primary
versus secondary care might be greater in Scotland where, in
contrast to England, primary and secondary health care are
more integrated, and GPs with experience in dementia may
diagnose and initiate treatment [27]. In England and Wales,
NICE guidelines recommend specialist initiation [28], so it
might be harder for people with dementia, and those with
fewer economic resources especially, to access prescribing.
The Northern Irish health system is relatively less integrated,
however, so integration does not explain our ﬁndings from
this region.
Levels of investment in health, including memory services,
vary between UK countries since devolution. Government
health spending is lowest in England and highest in Scotland
and Northern Ireland, although these variations have declined
over the past decade [29]. We found the lowest overall pre-
scribing rates in Wales, where memory clinic funding per new
patient is half that of English memory clinics [30] and fewer
dementia cases are diagnosed compared with the other UK
countries [7].
Limitations
Having a dementia diagnosis depends on patients presenting
and doctors (usually in secondary care) recording a diagnosis.
Dementia is under-recorded in GP records [31]. In a UK
study higher diagnosis rates were associated with greater
practice deprivation, perhaps because deprived groups have
more chronic illnesses that are associated with dementia and
more frequent GP contact [32]. Multiple morbidity is more
common in deprived areas, so perhaps some of the
decreased prescribing in these areas might relate to concerns
about side effects in those who are more physically frail [12].
We do not know whether the large group of people with
subtype dementia unspeciﬁed had potentially treatable condi-
tions. Vascular dementia is the most common dementia for
which anti-dementia drugs are not indicated, and its prevalence
would be expected to be greater in more deprived groups who
have higher cardiovascular morbidity [33]. This could explain
the lower treatment rates with deprivation; in our sensitivity
analyses restricted to those with treatable subtypes, results were
in the same direction but of lower magnitude. This is probably
because subtype diagnoses are often entered into records when
medication is started; in a previous study, people from more
deprived groups were more likely to have a diagnosis of demen-
tia subtype unknown [10]. Treatments exclusively in secondary
care would have not been detected and this may have happened
more to those less deprived, as access to secondary care is
probably reduced by deprivation [23], thus excluding this group
could underestimate the extent of inequalities. Dementia is the
only UK licensed indication for cholinesterase inhibitors, and
prescribing for another disorder is unlikely. Some recorded
cases of dementia may be misdiagnosed.
The Townsend score characterises deprivation in a par-
ticular form: for example it does not measure wealth, social
mobility and educational attainment directly. Car ownership
is included in the score but this may be a less useful depriv-
ation index in urban compared with rural areas, illustrating
the importance of a composite measure. Some people will be
assigned the wrong deprivation level, because they live in a
neighbourhood that is more or less deprived than their per-
sonal circumstances, and this is most likely in dense, inner
city areas. Care home locations may not reﬂect the depriv-
ation level of residents, so for the minority of people with
dementia who live in care homes, scores may not have been
accurate. Townsend scores calculated at the enumeration
district level are however strongly correlated with individual
deprivation and are similarly predictive of health [34]. The
IMD is now most frequently used, but as it cannot be used
to directly compare the different UK countries [35], it was
not our primary outcome. In our sensitivity analysis, ﬁndings
using the Townsend and IMD indices were very similar.
Conclusions
People with dementia who were least deprived were 25%
more likely than the most deprived to be prescribed anti-
dementia medication. This ﬁnding appeared to be driven by
English practice data, while in Scottish and Northern Irish
practices there was no such evidence of inequity. These
differences could relate to health policies of the countries,
which have diverged since devolution. Higher overall anti-
dementia drug prescribing in Scottish and Northern Irish
practices and differing clinical guidelines in Scotland from
other UK countries might explain apparently greater equality
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in prescribing in these countries. Strategies to offer treatment
to more deprived people with dementia in England are ur-
gently needed. These should focus on increasing the propor-
tion of people with dementia of all severities offered drug
treatments, and seeking to ensure that future prescribing pol-
icies do not introduce barriers to care that are less penetrable
to people from the most deprived areas.
Key points
• Least deprived patients were 25% more likely to be initiated
on anti-dementia drugs than the most deprived in the UK.
• We found that there were inequalities by deprivation in anti-
dementia drug prescribing in England but not the other
UK countries.
• Strategies to offer treatment to more deprived people with
dementia in England are needed.
Authors’ contributions
All authors devised the study; R.L. undertook all analyses
and R.L. and C.C. drafted the paper. All authors were part of
the Steering group that managed the study, of which C.C.
was Principal Investigator. All authors revised the manuscript
critically for intellectual content and approved the ﬁnal
version.
Conflicts of interest
None declared.
Funding
With thanks to the Dunhill Medical trust for funding the
study.
Ethics approval
The data provider of THIN (CSD Medical Research UK) has
obtained overall ethical approval from the South East MREC.
As we used anonymised routinely collected data in this study,
we did not require further ethics approval, but we obtained
approval by the THIN Scientiﬁc Review Committee. We did
not recruit, approach or interview individual patients.
References
1. Matthews FE, Arthur A, Barnes LE et al. A two-decade com-
parison of prevalence of dementia in individuals aged 65 years
and older from three geographical areas of England: results of
the Cognitive Function and Ageing Study I and II. Lancet
2013; 382: 1405–12.
2. Knapp M, Prince M, Albanese E et al. Dementia UK. London:
Alzheimer’s Society, 2007.
3. NHS Quality Improvement Scotland. Standards for integrated
care pathways for mental health, 2007. http://www.emcdda.
europa.eu/attachements.cfm/att_231409_EN_UK54_Scotland_
Mental%20Health_2007.pdf. (3 November 2015, date last
accessed).
4. Duthie AC, Banerjee S. Use of anti dementia medications in
Scotland: Views of old age psychiatrists. GeroPsych 2011; 24:
53–7.
5. Mukadam N, Livingston G, Rantell K, Rickman S. Diagnostic
rates and treatment of dementia before and after launch of a
national dementia policy: an observational study using English
national databases. BMJ Open 2014; 4: e004119.
6. Martinez C, Jones RW, Rietbrock S. Trends in the prevalence
of antipsychotic drug use among patients with Alzheimer’s
disease and other dementias including those treated with anti-
dementia drugs in the community in the UK: a cohort study.
BMJ Open 2013; 3: e002080.
7. Alzheimer Society. Mapping the Dementia Gap. London:
Alzheimer’s Society, 2013. http://www.alzheimers.org.uk/site/
scripts/documents_info.php?documentID=2165. (3 November
2015, date last accessed).
8. Cooper C, Tandy AR, Balamurali TBS, Livingston G. A sys-
tematic review and metaanalysis of ethnic differences in use of
dementia treatment, care and research. American Journal of
Geriatric Psychiatry 2010; 18: 193–203.
9. Zilkens RR, Duke J, Horner B, Semmens JB, Bruce DG.
Australian population trends and disparities in cholinesterase
inhibitor use, 2003 to 2010. Alzheimers Dement 2014; 10:
310–8.
10. Cooper C, Blanchard M, Selwood A, Livingston G. Antidementia
drugs: prescription by level of cognitive impairment or by socio-
economic group? Aging Mental Health 2010; 14: 85–9.
11. Matthews FE, McKeith I, Bond J, Brayne C. Reaching the
population with dementia drugs: what are the challenges? Int J
Geriatr Psychiatry 2007; 22: 627–31.
12. Mercer SW, Guthrie B, Furler J, Watt GCM, Hart JT.
Multimorbidity and the inverse care law in primary care. Br
Med J 2012; 344: e4152.
13. Seddon N. Quite Like Heaven? Options for the NHS in A
Consumer age. London: Civitas: Institute for the Study of Civil
Society, 2007.
14. Lis Y, Mann RD. The VAMP Research multi-purpose database
in the U.K. J Clin Epidemiol 1995; 48: 431–43.
15. British Medical Association. General Practice in the UK -
background brieﬁng, 2014. http://www.google.co.uk/url?
url=http://bma.org.uk/-/media/ﬁles/word%2520ﬁles/news
%2520views%2520analysis/press%2520brieﬁngs%2520new/
bmabrief_generalpractice.docx&rct=j&frm=1&q=&esrc=s&
sa=U&ved=0CBoQFjABahUKEwjr55KviPTIAhVM1RoK
HXoxCvk&usg=AFQjCNEEwhBHJYU-NKhrOB8oJAdl
ZJfdsw. (3 November 2015, date last accessed).
16. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability
of The Health Improvement Network (THIN) database:
demographics, chronic disease prevalence and mortality rates.
Informatics in primary care, 2011;19: 251–5.
17. Booth N. What are the Read Codes? Health Libraries Review
1994; 11: 177–82.
18. Horsfall L, Walters K, Petersen I. Identifying periods of ac-
ceptable computer usage in primary care research databases.
Pharmacoepidemiol Drug Saf 2013; 22: 64–9.
19. Maguire A, Blak BT, Thompson M. The importance of deﬁn-
ing periods of complete mortality reporting for research using
6
C. Cooper et al.
 at U
niversity College London on D
ecem
ber 10, 2015
http://ageing.oxfordjournals.org/
D
ow
nloaded from
 
automated data from primary care. Pharmacoepidemiol Drug
Saf 2009; 18: 76–83.
20. Townsend P, Phillimore M, Beattie A. Health and Deprivation:
Inequality and the North. London: Croom Helm Ltd, 1988.
21. UK government. Index of Multiple Deprivation. UK
government, 2015. http://data.gov.uk/dataset/index_of_multi
ple_deprivation_imd_2007. (3 November 2015, date last
accessed).
22. Amuah JE, Hogan DB, Eliasziw M et al. Persistence with cho-
linesterase inhibitor therapy in a population-based cohort of
patients with Alzheimer’s disease. Pharmacoepidemiol Drug
Saf 2010; 19: 670–9.
23. Qian WN, Schweizer TA, Fischer CE. Impact of socio-
economic status on initial clinical presentation to a memory
disorders clinic. Int Psychogeriatrics 2014; 26: 597–603.
24. Department of Health. The National Dementia Strategy,
2009. https://www.gov.uk/government/uploads/system/
uploads/attachment_data/ﬁle/168220/dh_094051.pdf. (3
November 2015, date last accessed).
25. National Institute for Clinical Excellence (NICE). How to
change practice, 2007. http://www.nice.org.uk/media/
default/about/what-we-do/into-practice/support-for-service-
improvement-and-audit/how-to-change-practice-barriers-to-
change.pdf. (3 November 2015, date last accessed).
26. Deparment of Health SSaPS. Improving dementia services
in northern Ireland. A Regional Strategy, 2011. http://www.
dhsspsni.gov.uk/improving-dementia-services-in-northern-
ireland-a-regional-strategy-november-2011.pdf. (3 November
2015, date last accessed).
27. Healthcare improvement Scotland. Healthcare Improvement
SCOTLAND, 2014. http://www.healthcareimprovementscotland.
org/our_work/technologies_and_medicines/mta_resources/
appraisal_217.aspx. (3 November 2015, date last accessed).
28. National Institute for Health and Clinical Excellence (NICE).
Alzheimer’s disease - donepezil, galantamine, rivastigmine and
memantine, 2011. Report No. TA 217.
29. Nufﬁeld trust. Health Care Spending per Person in the UK,
2015. http://www.nufﬁeldtrust.org.uk/data-and-charts/health-
spending-head-country. (3 November 2015, date last accessed).
30. Public Health Wales. Wales National Audit Memory Clinic
and Memory Assessment Services. Public Helath Wales,
2014. https://www.rcpsych.ac.uk/pdf/Wales%20National%
20Audit%20-%20Memory%20Clinics%20Aug%202014.pdf.
(3 November 2015, date last accessed).
31. Rait G, Walters K, Bottomley C, Petersen I, Iliffe S, Nazareth
I. Survival of people with clinical diagnosis of dementia in
primary care: cohort study. Br Med J 2010; 341: c3584.
32. Connolly A, Gaehl E, Martin H, Morris J, Purandare N.
Underdiagnosis of dementia in primary care: variations in the
observed prevalence and comparisons to the expected preva-
lence. Aging Mental Health 2011; 15: 978–84.
33. Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A.
Socioeconomic status and cardiovascular disease: risks and
implications for care. Nat Rev Cardiol 2009; 6: 712–22.
34. Adams J, Ryan V, White M. How accurate are Townsend
Deprivation Scores as predictors of self-reported health? A
comparison with individual level data. J Public Health 2005;
27: 101–6.
35. Payne RA, Abel GA. UK indices of multiple deprivation—a
way to make comparisons across constituent countries easier.
Health Statistics Quart 2012; 53. http://www.ons.gov.uk/ons/rel/
hsq/health-statistics-quarterly/no–53–spring-2012/uk-indices-of-
multiple-deprivation.html. (3 November 2015, date last accessed).
Received 16 June 2015; accepted in revised form
23 September 2015
7
Deprivation and access to anti-dementia drugs
 at U
niversity College London on D
ecem
ber 10, 2015
http://ageing.oxfordjournals.org/
D
ow
nloaded from
 
